ArticleIranian journal of pharmaceutical research : IJPR
Overcoming Liability of Outsidership Under Sanctions: A Capability-Based Framework from Emerging Market Pharmaceuticals.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sanctions and economic constraints impose substantial barriers to firm internationalization in emerging economies, particularly by exacerbating the liability of outsidership (LOO), defined as the disadvantages associated with exclusion from critical business networks. Despite extensive research on barriers to internationalization, limited attention has been paid to how firms in sanctioned economies leverage organizational capabilities to mitigate LOO at the micro level. Objectives: Drawing on the resource-based view, dynamic capabilities theory, and the Uppsala internationalization model, this study examined how pharmaceutical companies navigate LOO under sanctions through the strategic deployment of organizational capabilities. Methods: A qualitative multiple-case study was conducted in 10 Iranian pharmaceutical companies operating internationally under sanctions. Data were collected through interviews with senior executives and analyzed using thematic analysis. Results: The findings indicated three main interrelated routes through which capabilities mitigate LOO: 1) networking capability (NC) increases absorptive capacity (AC) by establishing trust-based relationships and facilitating knowledge exchange; 2) AC enhances operational capability (OC) by aligning operations with international benchmarks; and 3) NC, AC, and OC jointly reduce LOO by enabling access to alternative networks, strengthening operational legitimacy, and generating a competitive advantage. Conclusions: This study contributes to the internationalization literature by demonstrating how sanctions intensify LOO and necessitate the reconfiguration of firm capabilities. The findings show that dynamic capabilities interact with operational capabilities to support internationalization in constrained environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.